汉森制药2026年2月9日涨停分析：公司治理优化+核心产品优势+现金流改善

Core Viewpoint - Hansen Pharmaceutical (sz002412) experienced a trading halt on February 9, 2026, with a closing price of 8.35 yuan, marking a 10.01% increase, and a total market capitalization of 4.202 billion yuan [1] Group 1: Company Governance and Financial Performance - The company has recently revised its articles of association and over 20 management systems, enhancing governance and transparency in key areas such as board operations and information disclosure [2] - Hansen Pharmaceutical's main product, Si Mo Tang oral liquid, accounted for 81.98% of its revenue in 2023, indicating strong competitive advantages in its core products [2] - The operating cash flow for the third quarter of 2025 increased by 16.42% year-on-year, reaching 162 million yuan, reflecting improved cash flow conditions [2] - The pledge ratio of the controlling shareholder decreased from 16.28% to 4.72%, significantly reducing equity pledge risks [2] Group 2: Market Trends and Technical Indicators - The upcoming implementation of the National Medical Products Administration's "Special Regulations on the Registration of Traditional Chinese Medicine" is expected to benefit the company, as its main products have been fully revised and other products are progressing smoothly [2] - The traditional Chinese medicine sector has seen increased activity due to policy influences, with notable inflows of capital into the sector, contributing to a collective market response [2] - Technical indicators suggest that if the MACD forms a golden cross or if the stock price breaks through the upper Bollinger Band, it may attract more technical investors, further driving up the stock price [2]